Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

James Louis Januzzi Jr., M.D.

Co-Author

This page shows the publications co-authored by James Januzzi and Scott Solomon.
Connection Strength

2.866
  1. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. Circ Heart Fail. 2018 10; 11(10):e005133.
    View in: PubMed
    Score: 0.802
  2. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). Am Heart J. 2018 05; 199:130-136.
    View in: PubMed
    Score: 0.768
  3. Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. Circulation. 2021 Jun 08; 143(23):2316-2318.
    View in: PubMed
    Score: 0.242
  4. Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. Circ Heart Fail. 2020 06; 13(6):e006946.
    View in: PubMed
    Score: 0.225
  5. Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. JACC Heart Fail. 2020 May; 8(5):347-358.
    View in: PubMed
    Score: 0.222
  6. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019 Sep 17; 322(11):1085-1095.
    View in: PubMed
    Score: 0.214
  7. Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020 11 17; 76(20):2368-2378.
    View in: PubMed
    Score: 0.058
  8. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. JACC Heart Fail. 2020 12; 8(12):961-972.
    View in: PubMed
    Score: 0.058
  9. Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. Eur J Heart Fail. 2020 12; 22(12):2175-2186.
    View in: PubMed
    Score: 0.058
  10. Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. Eur J Heart Fail. 2020 11; 22(11):2018-2025.
    View in: PubMed
    Score: 0.058
  11. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. Circ Heart Fail. 2020 11; 13(11):e007829.
    View in: PubMed
    Score: 0.058
  12. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. Circulation. 2019 12 17; 140(25):2108-2118.
    View in: PubMed
    Score: 0.055
  13. Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. JACC Heart Fail. 2018 08; 6(8):619-632.
    View in: PubMed
    Score: 0.050
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.